查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867493

微生物組藥物：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Microbiome Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 157 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球微生物組藥物市場預計在 2024 年達到 5.68 億美元，預計到 2031 年將達到 32.96 億美元，在 2025 年至 2031 年的預測期內，複合年成長率將達到 30.1%。

微生物組藥物是基於人體共生微生物群及其代謝物開發的新型療法。這些療法包括活體治療產品（LBPs）、微生物群衍生代謝物、合成微生物製劑和標靶微生物組的小分子藥物。透過調節腸道、皮膚和呼吸道的宿主微生態環境，這些治療方法旨在恢復免疫平衡、調節代謝，並治療多種疾病，包括感染疾病、發炎性腸道疾病、代謝紊亂、神經精神疾病和癌症。隨著微生物組科學和合成生物學的快速突破，微生物組藥物正成為精準醫療的核心支柱，將治療模式從“殺滅微生物”轉變為“利用微生物”，從而實現系統性治療效果。

隨著精準醫療理念在全球範圍內不斷發展，微生物組藥物正迅速崛起，成為生物製藥創新領域的新興戰略前沿。多個國家的監管機構已為基於活體微生物群的產品設立了專門的核准途徑，加速了其臨床應用。根據公司年報顯示，多個處於III期臨床試驗階段的候選藥物即將進入商業化階段，預示市場即將迎來轉捩點。同時，合成生物學的進步使得建構具有穩定表達平台的工程化微生物療法成為可能，將微生物療法從糞便移植轉變為標準化藥物。在慢性病、免疫系統疾病和腫瘤治療領域日益成長的需求驅動下，全球投資和研發資源正集中於此變革性領域。

儘管微生物組藥物具有變革性潛力，但其應用仍處於早期階段，面臨技術和監管方面的許多不確定性。真實世界臨床數據顯示，部分早期產品有較高的患者間差異和療效不一致的問題，這給臨床標準化帶來了挑戰。活體生物製藥的生產、低溫運輸物流和品管要求構成了很高的技術壁壘，尤其是在規模化生產方面。此外，許多地區不完善的健保體系和臨床資金籌措機制也阻礙了其在短期內廣泛市場滲透。

在需求方面，對宿主-微生物組相互作用的深入了解正推動著從「補充益生菌」到「介入性處方藥」的轉變。醫生們對微生物組的治療方法越來越感興趣，尤其是在難治性困難梭狀芽孢桿菌傳染病、潰瘍性大腸炎、泛自閉症障礙和第2型糖尿病患者。領先的醫院正與製藥公司合作進行共同開發和真實世界研究，從而促進從學術試驗到常規臨床應用的過渡。隨著越來越多的候選藥物進入關鍵測試階段，微生物組藥物有望在全球處方藥市場中佔據一個獨特且極具潛力的細分市場。

本報告旨在對全球微生物組藥物市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名，並按地區/國家、類型和適應症對微生物組藥物進行分析。

本報告以收益為準，以 2024 年為基準年，對微生物組藥物市場規模、估算和預測進行了闡述，並包含了 2020 年至 2031 年的歷史數據和預測數據。報告運用定量和定性分析，幫助讀者制定業務/成長策略，評估市場競爭格局，分析自身在當前市場中的地位，並就微生物組藥物做出明智的商業決策。

市場區隔

公司

  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Finch Therapeutics
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • Ferring
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Vedanta Biosciences
  • Metabogen

按類型分類的細分市場

  • 口服劑型
  • 腸溶膠囊

症狀片段

  • 胃腸道疾病
  • 自體免疫疾病
  • 糖尿病
  • 癌症
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Microbiome Drugs was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3296 million by 2031 with a CAGR of 30.1% during the forecast period 2025-2031.

Microbiome Drugs refer to a new class of therapeutic agents developed based on human commensal microbiota and their metabolites. These include live biotherapeutic products (LBPs), microbiota-derived metabolites, synthetic microbial formulations, and microbiome-targeted small molecule drugs. By modulating the host's microecological environment-such as the gut, skin, or respiratory tract-these therapies aim to restore immune balance, regulate metabolism, and treat a broad spectrum of diseases including infectious conditions, inflammatory bowel diseases, metabolic disorders, neuropsychiatric illnesses, and cancers. As breakthroughs in microbiome science and synthetic biology continue to accelerate, microbiome drugs are emerging as a core pillar of precision medicine-transforming treatment paradigms from "killing microbes" to "leveraging microbes" for systemic therapeutic benefit.

As the concept of precision medicine continues to evolve globally, microbiome drugs are rapidly emerging as a new strategic frontier in biopharmaceutical innovation. Regulatory authorities in multiple countries have established dedicated review pathways for live microbiome-based products, accelerating clinical translation. According to annual reports from companies several Phase III candidates are approaching commercialization, signaling an imminent market inflection point. Meanwhile, advances in synthetic biology are enabling engineered microbial therapeutics with stable expression platforms, transforming microbiota therapies from fecal transplants into standardized pharmaceuticals. With chronic diseases, immune disorders, and oncology driving demand, global investment and R&D resources are converging toward this transformative sector.

Despite their disruptive potential, microbiome drugs remain in the early adoption phase, facing both technological and regulatory uncertainty. Real-world data reveal high inter-patient variability and inconsistent efficacy in some early-stage products, posing challenges for clinical standardization. Manufacturing, cold-chain logistics, and quality control requirements for live biotherapeutics impose high technical barriers, particularly in scaling up production. In addition, reimbursement frameworks and clinical funding mechanisms are still underdeveloped in many regions, slowing broad market penetration in the short term.

On the demand side, deeper insights into host-microbiome interactions are driving a shift from "supplemental probiotics" to "interventional prescription drugs." Physicians are increasingly open to microbiome-based therapies, especially for patients with refractory Clostridium difficile infections, ulcerative colitis, autism spectrum disorders, and type 2 diabetes. Leading hospitals are partnering with pharma companies to conduct joint development and real-world studies, fostering a transition from academic trials to routine clinical use. As more candidates reach critical trial milestones, microbiome drugs are poised to establish a distinct and high-potential segment within the global prescription drug market.

This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Microbiome Drugs by region & country, by Type, and by Symptom.

The Microbiome Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.

Market Segmentation

By Company

  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Finch Therapeutics
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • Ferring
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Vedanta Biosciences
  • Metabogen

Segment by Type

  • Oral Dosage Form
  • Enteric Capsules

Segment by Symptom

  • Gastrointestinal Disorders
  • Autoimmune Disorders
  • Diabetes
  • Cancer
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Microbiome Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Symptom, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Microbiome Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Microbiome Drugs in country level. It provides sigmate data by Type, and by Symptom for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Microbiome Drugs Product Introduction
  • 1.2 Global Microbiome Drugs Market Size Forecast (2020-2031)
  • 1.3 Microbiome Drugs Market Trends & Drivers
    • 1.3.1 Microbiome Drugs Industry Trends
    • 1.3.2 Microbiome Drugs Market Drivers & Opportunity
    • 1.3.3 Microbiome Drugs Market Challenges
    • 1.3.4 Microbiome Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Microbiome Drugs Players Revenue Ranking (2024)
  • 2.2 Global Microbiome Drugs Revenue by Company (2020-2025)
  • 2.3 Key Companies Microbiome Drugs Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Microbiome Drugs Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Microbiome Drugs
  • 2.6 Microbiome Drugs Market Competitive Analysis
    • 2.6.1 Microbiome Drugs Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Microbiome Drugs Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Oral Dosage Form
    • 3.1.2 Enteric Capsules
  • 3.2 Global Microbiome Drugs Sales Value by Type
    • 3.2.1 Global Microbiome Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Microbiome Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Microbiome Drugs Sales Value, by Type (%) (2020-2031)

4 Segmentation by Symptom

  • 4.1 Introduction by Symptom
    • 4.1.1 Gastrointestinal Disorders
    • 4.1.2 Autoimmune Disorders
    • 4.1.3 Diabetes
    • 4.1.4 Cancer
    • 4.1.5 Others
  • 4.2 Global Microbiome Drugs Sales Value by Symptom
    • 4.2.1 Global Microbiome Drugs Sales Value by Symptom (2020 VS 2024 VS 2031)
    • 4.2.2 Global Microbiome Drugs Sales Value, by Symptom (2020-2031)
    • 4.2.3 Global Microbiome Drugs Sales Value, by Symptom (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Microbiome Drugs Sales Value by Region
    • 5.1.1 Global Microbiome Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Microbiome Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Microbiome Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Microbiome Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Microbiome Drugs Sales Value, 2020-2031
    • 5.2.2 North America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Microbiome Drugs Sales Value, 2020-2031
    • 5.3.2 Europe Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Microbiome Drugs Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Microbiome Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Microbiome Drugs Sales Value, 2020-2031
    • 5.5.2 South America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Microbiome Drugs Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Microbiome Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Microbiome Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Microbiome Drugs Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Microbiome Drugs Sales Value, 2020-2031
    • 6.3.2 United States Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Microbiome Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Microbiome Drugs Sales Value, 2020-2031
    • 6.5.2 China Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Microbiome Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Microbiome Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Microbiome Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Microbiome Drugs Sales Value, 2020-2031
    • 6.9.2 India Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Microbiome Drugs Sales Value by Symptom, 2024 VS 2031

7 Company Profiles

  • 7.1 Seres Therapeutics
    • 7.1.1 Seres Therapeutics Profile
    • 7.1.2 Seres Therapeutics Main Business
    • 7.1.3 Seres Therapeutics Microbiome Drugs Products, Services and Solutions
    • 7.1.4 Seres Therapeutics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Seres Therapeutics Recent Developments
  • 7.2 Assembly Biosciences
    • 7.2.1 Assembly Biosciences Profile
    • 7.2.2 Assembly Biosciences Main Business
    • 7.2.3 Assembly Biosciences Microbiome Drugs Products, Services and Solutions
    • 7.2.4 Assembly Biosciences Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Assembly Biosciences Recent Developments
  • 7.3 Synthetic Biologics
    • 7.3.1 Synthetic Biologics Profile
    • 7.3.2 Synthetic Biologics Main Business
    • 7.3.3 Synthetic Biologics Microbiome Drugs Products, Services and Solutions
    • 7.3.4 Synthetic Biologics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Synthetic Biologics Recent Developments
  • 7.4 Finch Therapeutics
    • 7.4.1 Finch Therapeutics Profile
    • 7.4.2 Finch Therapeutics Main Business
    • 7.4.3 Finch Therapeutics Microbiome Drugs Products, Services and Solutions
    • 7.4.4 Finch Therapeutics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Finch Therapeutics Recent Developments
  • 7.5 PureTech
    • 7.5.1 PureTech Profile
    • 7.5.2 PureTech Main Business
    • 7.5.3 PureTech Microbiome Drugs Products, Services and Solutions
    • 7.5.4 PureTech Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.5.5 PureTech Recent Developments
  • 7.6 Synlogic
    • 7.6.1 Synlogic Profile
    • 7.6.2 Synlogic Main Business
    • 7.6.3 Synlogic Microbiome Drugs Products, Services and Solutions
    • 7.6.4 Synlogic Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Synlogic Recent Developments
  • 7.7 Enterome BioScience
    • 7.7.1 Enterome BioScience Profile
    • 7.7.2 Enterome BioScience Main Business
    • 7.7.3 Enterome BioScience Microbiome Drugs Products, Services and Solutions
    • 7.7.4 Enterome BioScience Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Enterome BioScience Recent Developments
  • 7.8 4D Pharma
    • 7.8.1 4D Pharma Profile
    • 7.8.2 4D Pharma Main Business
    • 7.8.3 4D Pharma Microbiome Drugs Products, Services and Solutions
    • 7.8.4 4D Pharma Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.8.5 4D Pharma Recent Developments
  • 7.9 Second Genome
    • 7.9.1 Second Genome Profile
    • 7.9.2 Second Genome Main Business
    • 7.9.3 Second Genome Microbiome Drugs Products, Services and Solutions
    • 7.9.4 Second Genome Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Second Genome Recent Developments
  • 7.10 Ferring
    • 7.10.1 Ferring Profile
    • 7.10.2 Ferring Main Business
    • 7.10.3 Ferring Microbiome Drugs Products, Services and Solutions
    • 7.10.4 Ferring Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Ferring Recent Developments
  • 7.11 C3 Jian
    • 7.11.1 C3 Jian Profile
    • 7.11.2 C3 Jian Main Business
    • 7.11.3 C3 Jian Microbiome Drugs Products, Services and Solutions
    • 7.11.4 C3 Jian Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.11.5 C3 Jian Recent Developments
  • 7.12 Rebiotix
    • 7.12.1 Rebiotix Profile
    • 7.12.2 Rebiotix Main Business
    • 7.12.3 Rebiotix Microbiome Drugs Products, Services and Solutions
    • 7.12.4 Rebiotix Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Rebiotix Recent Developments
  • 7.13 MicroBiome Therapeutics LLC
    • 7.13.1 MicroBiome Therapeutics LLC Profile
    • 7.13.2 MicroBiome Therapeutics LLC Main Business
    • 7.13.3 MicroBiome Therapeutics LLC Microbiome Drugs Products, Services and Solutions
    • 7.13.4 MicroBiome Therapeutics LLC Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.13.5 MicroBiome Therapeutics LLC Recent Developments
  • 7.14 Metabiomics
    • 7.14.1 Metabiomics Profile
    • 7.14.2 Metabiomics Main Business
    • 7.14.3 Metabiomics Microbiome Drugs Products, Services and Solutions
    • 7.14.4 Metabiomics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Metabiomics Recent Developments
  • 7.15 Ritter Pharmaceuticals
    • 7.15.1 Ritter Pharmaceuticals Profile
    • 7.15.2 Ritter Pharmaceuticals Main Business
    • 7.15.3 Ritter Pharmaceuticals Microbiome Drugs Products, Services and Solutions
    • 7.15.4 Ritter Pharmaceuticals Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Ritter Pharmaceuticals Recent Developments
  • 7.16 Symberix
    • 7.16.1 Symberix Profile
    • 7.16.2 Symberix Main Business
    • 7.16.3 Symberix Microbiome Drugs Products, Services and Solutions
    • 7.16.4 Symberix Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.16.5 Symberix Recent Developments
  • 7.17 OpenBiome
    • 7.17.1 OpenBiome Profile
    • 7.17.2 OpenBiome Main Business
    • 7.17.3 OpenBiome Microbiome Drugs Products, Services and Solutions
    • 7.17.4 OpenBiome Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.17.5 OpenBiome Recent Developments
  • 7.18 Azitra
    • 7.18.1 Azitra Profile
    • 7.18.2 Azitra Main Business
    • 7.18.3 Azitra Microbiome Drugs Products, Services and Solutions
    • 7.18.4 Azitra Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.18.5 Azitra Recent Developments
  • 7.19 Symbiotix Biotherapies
    • 7.19.1 Symbiotix Biotherapies Profile
    • 7.19.2 Symbiotix Biotherapies Main Business
    • 7.19.3 Symbiotix Biotherapies Microbiome Drugs Products, Services and Solutions
    • 7.19.4 Symbiotix Biotherapies Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.19.5 Symbiotix Biotherapies Recent Developments
  • 7.20 Vedanta Biosciences
    • 7.20.1 Vedanta Biosciences Profile
    • 7.20.2 Vedanta Biosciences Main Business
    • 7.20.3 Vedanta Biosciences Microbiome Drugs Products, Services and Solutions
    • 7.20.4 Vedanta Biosciences Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.20.5 Vedanta Biosciences Recent Developments
  • 7.21 Metabogen
    • 7.21.1 Metabogen Profile
    • 7.21.2 Metabogen Main Business
    • 7.21.3 Metabogen Microbiome Drugs Products, Services and Solutions
    • 7.21.4 Metabogen Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.21.5 Metabogen Recent Developments

8 Industry Chain Analysis

  • 8.1 Microbiome Drugs Industrial Chain
  • 8.2 Microbiome Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Microbiome Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Microbiome Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Microbiome Drugs Market Trends
  • Table 2. Microbiome Drugs Market Drivers & Opportunity
  • Table 3. Microbiome Drugs Market Challenges
  • Table 4. Microbiome Drugs Market Restraints
  • Table 5. Global Microbiome Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Microbiome Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Microbiome Drugs Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Microbiome Drugs Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Microbiome Drugs
  • Table 10. Global Microbiome Drugs Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Microbiome Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Microbiome Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Microbiome Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Microbiome Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Microbiome Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Microbiome Drugs Sales Value by Symptom: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Microbiome Drugs Sales Value by Symptom (2020-2025) & (US$ Million)
  • Table 20. Global Microbiome Drugs Sales Value by Symptom (2026-2031) & (US$ Million)
  • Table 21. Global Microbiome Drugs Sales Market Share in Value by Symptom (2020-2025)
  • Table 22. Global Microbiome Drugs Sales Market Share in Value by Symptom (2026-2031)
  • Table 23. Global Microbiome Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Microbiome Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Microbiome Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Microbiome Drugs Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Microbiome Drugs Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Microbiome Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Microbiome Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Microbiome Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Seres Therapeutics Basic Information List
  • Table 32. Seres Therapeutics Description and Business Overview
  • Table 33. Seres Therapeutics Microbiome Drugs Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Microbiome Drugs Business of Seres Therapeutics (2020-2025)
  • Table 35. Seres Therapeutics Recent Developments
  • Table 36. Assembly Biosciences Basic Information List
  • Table 37. Assembly Biosciences Description and Business Overview
  • Table 38. Assembly Biosciences Microbiome Drugs Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Microbiome Drugs Business of Assembly Biosciences (2020-2025)
  • Table 40. Assembly Biosciences Recent Developments
  • Table 41. Synthetic Biologics Basic Information List
  • Table 42. Synthetic Biologics Description and Business Overview
  • Table 43. Synthetic Biologics Microbiome Drugs Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Microbiome Drugs Business of Synthetic Biologics (2020-2025)
  • Table 45. Synthetic Biologics Recent Developments
  • Table 46. Finch Therapeutics Basic Information List
  • Table 47. Finch Therapeutics Description and Business Overview
  • Table 48. Finch Therapeutics Microbiome Drugs Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Microbiome Drugs Business of Finch Therapeutics (2020-2025)
  • Table 50. Finch Therapeutics Recent Developments
  • Table 51. PureTech Basic Information List
  • Table 52. PureTech Description and Business Overview
  • Table 53. PureTech Microbiome Drugs Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Microbiome Drugs Business of PureTech (2020-2025)
  • Table 55. PureTech Recent Developments
  • Table 56. Synlogic Basic Information List
  • Table 57. Synlogic Description and Business Overview
  • Table 58. Synlogic Microbiome Drugs Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Microbiome Drugs Business of Synlogic (2020-2025)
  • Table 60. Synlogic Recent Developments
  • Table 61. Enterome BioScience Basic Information List
  • Table 62. Enterome BioScience Description and Business Overview
  • Table 63. Enterome BioScience Microbiome Drugs Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Microbiome Drugs Business of Enterome BioScience (2020-2025)
  • Table 65. Enterome BioScience Recent Developments
  • Table 66. 4D Pharma Basic Information List
  • Table 67. 4D Pharma Description and Business Overview
  • Table 68. 4D Pharma Microbiome Drugs Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Microbiome Drugs Business of 4D Pharma (2020-2025)
  • Table 70. 4D Pharma Recent Developments
  • Table 71. Second Genome Basic Information List
  • Table 72. Second Genome Description and Business Overview
  • Table 73. Second Genome Microbiome Drugs Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Microbiome Drugs Business of Second Genome (2020-2025)
  • Table 75. Second Genome Recent Developments
  • Table 76. Ferring Basic Information List
  • Table 77. Ferring Description and Business Overview
  • Table 78. Ferring Microbiome Drugs Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Microbiome Drugs Business of Ferring (2020-2025)
  • Table 80. Ferring Recent Developments
  • Table 81. C3 Jian Basic Information List
  • Table 82. C3 Jian Description and Business Overview
  • Table 83. C3 Jian Microbiome Drugs Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Microbiome Drugs Business of C3 Jian (2020-2025)
  • Table 85. C3 Jian Recent Developments
  • Table 86. Rebiotix Basic Information List
  • Table 87. Rebiotix Description and Business Overview
  • Table 88. Rebiotix Microbiome Drugs Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Microbiome Drugs Business of Rebiotix (2020-2025)
  • Table 90. Rebiotix Recent Developments
  • Table 91. MicroBiome Therapeutics LLC Basic Information List
  • Table 92. MicroBiome Therapeutics LLC Description and Business Overview
  • Table 93. MicroBiome Therapeutics LLC Microbiome Drugs Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Microbiome Drugs Business of MicroBiome Therapeutics LLC (2020-2025)
  • Table 95. MicroBiome Therapeutics LLC Recent Developments
  • Table 96. Metabiomics Basic Information List
  • Table 97. Metabiomics Description and Business Overview
  • Table 98. Metabiomics Microbiome Drugs Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Microbiome Drugs Business of Metabiomics (2020-2025)
  • Table 100. Metabiomics Recent Developments
  • Table 101. Ritter Pharmaceuticals Basic Information List
  • Table 102. Ritter Pharmaceuticals Description and Business Overview
  • Table 103. Ritter Pharmaceuticals Microbiome Drugs Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Microbiome Drugs Business of Ritter Pharmaceuticals (2020-2025)
  • Table 105. Ritter Pharmaceuticals Recent Developments
  • Table 106. Symberix Basic Information List
  • Table 107. Symberix Description and Business Overview
  • Table 108. Symberix Microbiome Drugs Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Microbiome Drugs Business of Symberix (2020-2025)
  • Table 110. Symberix Recent Developments
  • Table 111. OpenBiome Basic Information List
  • Table 112. OpenBiome Description and Business Overview
  • Table 113. OpenBiome Microbiome Drugs Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Microbiome Drugs Business of OpenBiome (2020-2025)
  • Table 115. OpenBiome Recent Developments
  • Table 116. Azitra Basic Information List
  • Table 117. Azitra Description and Business Overview
  • Table 118. Azitra Microbiome Drugs Products, Services and Solutions
  • Table 119. Revenue (US$ Million) in Microbiome Drugs Business of Azitra (2020-2025)
  • Table 120. Azitra Recent Developments
  • Table 121. Symbiotix Biotherapies Basic Information List
  • Table 122. Symbiotix Biotherapies Description and Business Overview
  • Table 123. Symbiotix Biotherapies Microbiome Drugs Products, Services and Solutions
  • Table 124. Revenue (US$ Million) in Microbiome Drugs Business of Symbiotix Biotherapies (2020-2025)
  • Table 125. Symbiotix Biotherapies Recent Developments
  • Table 126. Vedanta Biosciences Basic Information List
  • Table 127. Vedanta Biosciences Description and Business Overview
  • Table 128. Vedanta Biosciences Microbiome Drugs Products, Services and Solutions
  • Table 129. Revenue (US$ Million) in Microbiome Drugs Business of Vedanta Biosciences (2020-2025)
  • Table 130. Vedanta Biosciences Recent Developments
  • Table 131. Metabogen Basic Information List
  • Table 132. Metabogen Description and Business Overview
  • Table 133. Metabogen Microbiome Drugs Products, Services and Solutions
  • Table 134. Revenue (US$ Million) in Microbiome Drugs Business of Metabogen (2020-2025)
  • Table 135. Metabogen Recent Developments
  • Table 136. Key Raw Materials Lists
  • Table 137. Raw Materials Key Suppliers Lists
  • Table 138. Microbiome Drugs Downstream Customers
  • Table 139. Microbiome Drugs Distributors List
  • Table 140. Research Programs/Design for This Report
  • Table 141. Key Data Information from Secondary Sources
  • Table 142. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Microbiome Drugs Product Picture
  • Figure 2. Global Microbiome Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Microbiome Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Microbiome Drugs Report Years Considered
  • Figure 5. Global Microbiome Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Microbiome Drugs Revenue in 2024
  • Figure 7. Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Oral Dosage Form Picture
  • Figure 9. Enteric Capsules Picture
  • Figure 10. Global Microbiome Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Microbiome Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Gastrointestinal Disorders
  • Figure 13. Product Picture of Autoimmune Disorders
  • Figure 14. Product Picture of Diabetes
  • Figure 15. Product Picture of Cancer
  • Figure 16. Product Picture of Others
  • Figure 17. Global Microbiome Drugs Sales Value by Symptom (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Microbiome Drugs Sales Value Market Share by Symptom, 2024 & 2031
  • Figure 19. North America Microbiome Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Microbiome Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Microbiome Drugs Sales Value (%), (2020-2031)
  • Figure 30. United States Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 33. Europe Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 36. China Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 39. Japan Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 42. South Korea Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 45. Southeast Asia Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 48. India Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 51. Microbiome Drugs Industrial Chain
  • Figure 52. Microbiome Drugs Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed